Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial

Article Gastroenterology & Hepatology

Dynamic changes in antibiotic resistance genes and gut microbiota after Helicobacter pylori eradication therapies

Lingling Wang et al.

Summary: The study revealed dynamic alterations in gut microbiota and ARGs induced by various eradication therapies, which may have implications for antibiotic choices in eradication therapy.

HELICOBACTER (2022)

添加到收藏夹

Article Medicine, General & Internal

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

Christopher J. L. Murray et al.

Summary: Antimicrobial resistance (AMR) poses a significant threat to global human health, and this study provides the most comprehensive estimates of AMR burden to date. By estimating deaths and disability-adjusted life-years (DALYs) associated with bacterial AMR in 204 countries and territories in 2019, the study highlights the impact of resistance and the leading pathogen-drug combinations contributing to it.

LANCET (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship

David Y. Graham et al.

Summary: This article provides guidance on transitioning Helicobacter pylori therapy guidelines to adhere to the principles of antimicrobial stewardship. The goals of antimicrobial stewardship are optimizing antibiotic use and reducing resistance. Only therapies with at least a 90% cure rate should be considered acceptable. The article also emphasizes the importance of surveillance and recommends treatment guidelines consistent with ASID white paper.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report

Peter Malfertheiner et al.

Summary: Helicobacter pylori infection is recognized as an infectious disease and requires optimized management to prevent complications and gastric cancer. Continuous updates in treatment strategies and testing methods are necessary due to rising antibiotic resistance and the impact on gut microbiota.

GUT (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community

Francis Megraud et al.

Summary: The study confirmed a positive correlation between macrolide and quinolone consumption in the community and corresponding H. pylori resistance in European countries. Therefore, treatment of H. pylori with clarithromycin and levofloxacin should involve susceptibility testing in most European countries before starting the treatment.

GUT (2021)

添加到收藏夹

Article Medicine, General & Internal

Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration

Ashwini Sankar et al.

Summary: This study found an overall decline in prescribing of fluoroquinolones after the FDA warnings in 2013 and 2016. Understanding the association of physician and organizational characteristics with fluoroquinolone prescribing behavior may ultimately help to identify mechanisms to improve de-adoption.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Medicine, General & Internal